Analysis: New drug launch prices outpace value, rising 24% to 35%

· Health · United States

A new report from the Institute for Clinical and Economic Review (ICER) found that the median list price of drugs at launch rose 24% from 2022 to 2025, while net prices — adjusted for inflation and manufacturer discounts — rose even faster, by 35%, to $257,000 last year from $173,000 in 2022. ICER also concluded that the majority of newly launched medicines were priced well above its cost-effectiveness guidelines. The analysis covers 202 newly launched medicines and adds to a long-running debate over whether launch prices reflect clinical benefit. The findings land as payers and policymakers scrutinize drug pricing, and they suggest that even after confidential rebates, the effective cost of new medicines is climbing faster than their measured worth.

Why it matters：Launch pricing is where drugmakers' R&D bets meet payer budgets, and ICER's verdict that most new medicines exceed cost-effectiveness thresholds gives payers and governments fresh ammunition in pricing negotiations.

Key points

  • The median net price for 202 newly launched medicines rose to $257,000 last year from $173,000 in 2022.
  • ICER said most new drugs were priced well above its cost-effectiveness guidelines.

Sources (original reporting)

More stories from this day